Compare XPOF & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPOF | VNDA |
|---|---|---|
| Founded | 2017 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.5M | 289.0M |
| IPO Year | 2021 | 2006 |
| Metric | XPOF | VNDA |
|---|---|---|
| Price | $7.86 | $6.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | $11.69 | ★ $14.00 |
| AVG Volume (30 Days) | 656.8K | ★ 1.3M |
| Earning Date | 11-06-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $315,135,000.00 | $212,074,000.00 |
| Revenue This Year | N/A | $12.01 |
| Revenue Next Year | N/A | $21.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 11.12 |
| 52 Week Low | $5.38 | $3.81 |
| 52 Week High | $18.87 | $6.88 |
| Indicator | XPOF | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 67.46 | 63.55 |
| Support Level | $6.73 | $4.89 |
| Resistance Level | $8.23 | $6.88 |
| Average True Range (ATR) | 0.39 | 0.39 |
| MACD | 0.21 | 0.16 |
| Stochastic Oscillator | 87.60 | 70.10 |
Xponential Fitness Inc is a curator of boutique fitness brands. Its diversified portfolio of brands includes Club Pilates, a Pilates brand in the United States; CycleBar, an indoor cycling brand in the United States; StretchLab, a concept offering one-on-one and group stretching services; Row House, a high-energy, low-impact indoor rowing workout; AKT, a dance-based cardio workout combining toning, interval and circuit training; YogaSix a franchised yoga brand; Pure Barre, a total body workout that uses the ballet barre to perform small isometric movements; Stride, a treadmill-based cardio and strength training concept; Rumble, a boxing-inspired full-body workout; and BFT, a functional training and strength-based program. Its key revenue source is franchise income.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.